Plus Therapeutics Secures FDA Conditional Acceptance for REYOBIQ™ as Lead Therapy Name

Plus Therapeutics  has announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted REYOBIQ™ as the proprietary name for its lead radiotherapeutic candidate. The company, focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, will officially submit a request for proprietary name review upon filing its New Drug Application (NDA). This milestone strengthens the branding of rhenium Re186 obisbemeda, which will now be referenced as REYOBIQ™ in all communications.

According to Russ Havranek, VP of Corporate Strategy and New Product Planning, establishing the REYOBIQ™ brand marks a crucial step toward commercialization. By introducing a recognizable name, Plus Therapeutics aims to enhance engagement with investigators, investors, and patients, reinforcing its mission to advance targeted radiotherapeutics for leptomeningeal metastases (LM) and glioblastoma (GBM). The company remains committed to driving innovation and improving patient outcomes through its cutting-edge radiotherapeutic platform.